Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 323 followers
Latest posts
Last updated about 3 hours ago
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
about 3 hours ago
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
13 days ago
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and...
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
14 days ago
Susvimo is under review with the EMA and once approved will be...
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
19 days ago
Phase III trial informed by comprehensive KARDIA data set generated through three...
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
24 days ago
The $700 million project is part of Roche’s $50 billion investment in...
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
about 2 months ago
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision...
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
about 2 months ago
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust...
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
about 2 months ago
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
about 2 months ago
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange...
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
about 2 months ago
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test...
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
about 2 months ago
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than...
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
about 2 months ago
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will...